Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Free Cash Flow (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Free Cash Flow data on record, last reported at -$264000.0 in Q3 2025.

  • For Q3 2025, Free Cash Flow rose 84.62% year-over-year to -$264000.0; the TTM value through Sep 2025 reached -$1.4 million, up 77.94%, while the annual FY2024 figure was -$4.3 million, 79.6% up from the prior year.
  • Free Cash Flow reached -$264000.0 in Q3 2025 per CYCN's latest filing, up from -$503000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $360000.0 in Q4 2024 and bottomed at -$14.5 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$5.5 million, with a median of -$6.2 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: tumbled 96.37% in 2022, then surged 123.36% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$8.6 million in 2021, then grew by 18.39% to -$7.0 million in 2022, then soared by 78.12% to -$1.5 million in 2023, then soared by 123.36% to $360000.0 in 2024, then crashed by 173.33% to -$264000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$264000.0 in Q3 2025, -$503000.0 in Q2 2025, and -$968000.0 in Q1 2025.